| Rosiglitazone | Approved Investigational | SLC25A30 | 253512 |
upregulated | rosiglitazone results in increased expression of SLC25A30 mRNA | 13q14.13 | |
| Rosiglitazone | Approved Investigational | SLC26A11 | 284129 |
upregulated | rosiglitazone results in increased expression of SLC26A11 mRNA | 17q25.3 | |
| Rosiglitazone | Approved Investigational | SLC27A1 | 376497 |
downregulated | rosiglitazone results in decreased expression of SLC27A1 mRNA | 19p13.11 | |
| Rosiglitazone | Approved Investigational | SLC27A2 | 11001 |
downregulated | rosiglitazone results in decreased expression of SLC27A2 mRNA | 15q21.2 | |
| Rosiglitazone | Approved Investigational | SLC27A2 | 11001 |
upregulated | rosiglitazone results in increased expression of SLC27A2 mRNA | 15q21.2 | |
| Rosiglitazone | Approved Investigational | SLC28A1 | 9154 |
downregulated | rosiglitazone results in decreased expression of SLC28A1 mRNA | 15q25.3 | |
| Rosiglitazone | Approved Investigational | SLC29A4 | 222962 |
upregulated | rosiglitazone results in increased expression of SLC29A4 mRNA | 7p22.1 | |
| Rosiglitazone | Approved Investigational | SLC2A1 | 6513 |
downregulated | rosiglitazone results in decreased expression of SLC2A1 mRNA | 1p34.2 | |
| Rosiglitazone | Approved Investigational | SLC2A1 | 6513 |
upregulated | rosiglitazone results in increased expression of SLC2A1 mRNA | 1p34.2 | |
| Rosiglitazone | Approved Investigational | SLC2A4 | 6517 |
upregulated | rosiglitazone results in increased expression of SLC2A4 mRNA | 17p13.1 | |
| Rosiglitazone | Approved Investigational | SLC37A4 | 2542 |
downregulated | rosiglitazone results in decreased expression of SLC37A4 mRNA | 11q23.3 | |
| Rosiglitazone | Approved Investigational | SLC38A3 | 10991 |
downregulated | rosiglitazone results in decreased expression of SLC38A3 mRNA | 3p21.31 | |
| Rosiglitazone | Approved Investigational | SLC3A2 | 6520 |
upregulated | rosiglitazone results in increased expression of SLC3A2 mRNA | 11q12.3 | |
| Rosiglitazone | Approved Investigational | SLC51A | 200931 |
downregulated | rosiglitazone results in decreased expression of SLC51A mRNA | 3q29 | |
| Rosiglitazone | Approved Investigational | SLC51B | 123264 |
upregulated | rosiglitazone results in increased expression of SLC51B mRNA | 15q22.31 | |
| Rosiglitazone | Approved Investigational | SLCO2A1 | 6578 |
upregulated | rosiglitazone results in increased expression of SLCO2A1 mRNA | 3q22.1-q22.2 | |
| Rosiglitazone | Approved Investigational | SLCO2B1 | 11309 |
downregulated | rosiglitazone results in decreased expression of SLCO2B1 mRNA | 11q13 | |
| Rosiglitazone | Approved Investigational | SLITRK4 | 139065 |
upregulated | rosiglitazone results in increased expression of SLITRK4 mRNA | Xq27.3 | |
| Rosiglitazone | Approved Investigational | SNAI3 | 333929 |
upregulated | rosiglitazone results in increased expression of SNAI3 mRNA | 16q24.3 | |
| Rosiglitazone | Approved Investigational | SOD2 | 6648 |
downregulated | rosiglitazone results in decreased expression of SOD2 mRNA | 6q25.3 | |
| Rosiglitazone | Approved Investigational | SOD2 | 6648 |
upregulated | rosiglitazone results in increased expression of SOD2 mRNA | 6q25.3 | |
| Rosiglitazone | Approved Investigational | SOHLH2 | 54937 |
upregulated | rosiglitazone results in increased expression of SOHLH2 mRNA | 13q13.3 | |
| Rosiglitazone | Approved Investigational | SORL1 | 6653 |
downregulated | rosiglitazone results in decreased expression of SORL1 mRNA | 11q24.1 | |
| Rosiglitazone | Approved Investigational | SOX13 | 9580 |
downregulated | rosiglitazone results in decreased expression of SOX13 mRNA | 1q32.1 | |
| Rosiglitazone | Approved Investigational | SOX4 | 6659 |
upregulated | rosiglitazone results in increased expression of SOX4 mRNA | 6p22.3 | |